MAGEA10 gene expression in non-small cell lung cancer and A549 cells, and the affinity of epitopes with the complex of HLA-A∗0201 alleles

Valmori, 2001, Frequent cytolytic T-cell responses to peptide MAGE-A10(254–262) in melanoma, Cancer Res., 61, 509 Valmori, 2002, Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity, J. Immunol., 168, 4231, 10.4049/jimmunol.168.8.4231 Rimoldi, 1999, CDNA and protein characterization of human MAGE-10, Int. J. Cancer, 82, 901, 10.1002/(SICI)1097-0215(19990909)82:6<901::AID-IJC21>3.0.CO;2-X http://www.proteinatlas.org/ accessed 22.01.2015. Chomez, 2001, An overview of the MAGE gene family with the identification of all human members of the family, Cancer Res., 61, 5544 Batchu, 2014, MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine, Jama Surg., 149, 451, 10.1001/jamasurg.2013.4113 Kozlowska, 2013, Therapeutic gene modified cell based cancer vaccines, Gene, 525, 200, 10.1016/j.gene.2013.03.056 Chinnasamy, 2011, A TCR targeting the HLA-A∗0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer, J. Immunol., 186, 685, 10.4049/jimmunol.1001775 Peled, 2009, MAGE A3 antigen-specific cancer immunotherapeutic, Immunotherapy, 1, 19, 10.2217/1750743X.1.1.19 Kobayashi, 2001, Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles, Cancer Res., 61, 4773 Zhou, 2005, Identification of two naturally presented MAGE antigenic peptides from a patient with hepatocellular carcinoma by mass spectrometry, Immunol. Lett., 99, 113, 10.1016/j.imlet.2005.02.007 Akira, 2001, Toll-like receptors: critical proteins linking innate and acquired immunity, Nat. Immunol., 2, 675, 10.1038/90609 Nakajima, 1992, Structure of the extracellular polysaccharide from slime-forming Lactococcus lactis subsp. cremoris SBT 0495, Carbohydr. Res., 224, 245, 10.1016/0008-6215(92)84110-E Higashimura, 2000, Solution properties of viilian, the exopolysaccharide from Lactococcus lactis subsp. cremoris SBT 0495, Biopolymers, 54, 143, 10.1002/1097-0282(200008)54:2<143::AID-BIP7>3.0.CO;2-Q Kitazawa, 1993, B-cell mitogen produced by slime-forming, encapsulated Lactococcus lactis ssp. cremoris isolated from ropy sour milk, viili, J. Dairy Sci., 76, 1514, 10.3168/jds.S0022-0302(93)77483-4 Kitazawa, 2008, Development of molecular immunoassay system for probiotics via toll-like receptors based on food immunology, Anim. Sci. J., 79, 11, 10.1111/j.1740-0929.2007.00491.x-i1 Kekkonen, 2008, Probiotic Leuconostoc mesenteroides ssp cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production, World J. Gastroenterol., 14, 1192, 10.3748/wjg.14.1192 Cesson, 2011, MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes, Cancer Immunol. Immunother., 60, 23, 10.1007/s00262-010-0916-z Zorn, 1999, A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion, Eur. J. Immunol., 29, 602, 10.1002/(SICI)1521-4141(199902)29:02<602::AID-IMMU602>3.0.CO;2-Y Zhang, 2002, A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes, Tissue Antigens, 60, 365, 10.1034/j.1399-0039.2002.600503.x Hillig, 2001, High-resolution structure of HLA-A∗0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene, J. Mol. Biol., 310, 1167, 10.1006/jmbi.2001.4816 Urgard, 2011, Metagenes associated with survival in non-small cell lung cancer, Cancer Inform., 10, 175, 10.4137/CIN.S7135 Lokk, 2012, Methylation markers of early-stage non-small cell lung cancer, PLoS ONE, 7, e39813, 10.1371/journal.pone.0039813 Staub, 1965, Removal of protein-Sevag method, Methods Carbohydr. Chem., 5, 5 Wu, 2013, Nitric oxide and interleukins are involved in cell proliferation of RAW264.7 macrophages activated by viili exopolysaccharides, Inflammation, 36, 954, 10.1007/s10753-013-9626-y Huang, 1999, Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma, J. Immunol., 162, 6849, 10.4049/jimmunol.162.11.6849 Chen, 2001, Expressions of cancer-testis antigens in human hepatocellular carcinomas, Cancer Lett., 164, 189, 10.1016/S0304-3835(01)00379-2 Douat-Casassus, 2006, Covalent modification of a melanoma-derived antigenic peptide with a natural quinone methide. Preliminary chemical, molecular modelling and immunological evaluation studies, Mol. BioSyst., 2, 240, 10.1039/b518044a N. Eswar, B. Webb, M.A. Marti-Renom, M.S. Madhusudhan, D. Eramian, M.Y. Shen, et al. Comparative protein structure modeling using Modeller. Current protocols in bioinformatics/editoral board, Andreas D Baxevanis [et al.]. Chapter 5 (2006): Unit 5 6. Marti-Renom, 2000, Comparative protein structure modeling of genes and genomes, Annu. Rev. Biophys. Biomol. Struct., 29, 291, 10.1146/annurev.biophys.29.1.291 Sali, 1993, Comparative protein modelling by satisfaction of spatial restraints, J. Mol. Biol., 234, 779, 10.1006/jmbi.1993.1626 Fiser, 2000, Modeling of loops in protein structures, Protein Sci., 9, 1753, 10.1110/ps.9.9.1753 Jia, 2011, Identification of a new MAGE-A10 antigenic peptide presented by HLA-A∗0201 on tumor cells, Cancer Biol. Ther., 11, 395, 10.4161/cbt.11.4.14100 Andrade, 2008, Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients, Cancer Immun., 8, 2 Ayyoub, 2014, Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS, Cancer Immunol. Res., 2, 943, 10.1158/2326-6066.CIR-13-0211 Keogh, 2001, Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A∗0201-binding affinity, J. Immunol., 167, 787, 10.4049/jimmunol.167.2.787 Dutoit, 2001, Heterogeneous T-cell response to MAGE-A10254–262 high avidity-specific cytolytic T lymphocytes show superior antitumor activity, Cancer Res., 61, 5850 Cormier, 1999, Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model, Int. J. Cancer, 80, 781, 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A K. Lokk, V. Modhukur, B. Rajashekar, K. Martens, R. Magi, R. Kolde, et al. DNA methylome profiling of human tissues identifies global and tissue-specific methylation patterns. Genome Biol., 15 (2014) (4). J.K. Stratford, D.J. Bentrem, J.M. Anderson, C. Fan, K.A. Volmar, J.S. Marron, et al. A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. Plos Med., 7 (2010) (7). Kramer, 2005, MAGED4-expression in renal cell carcinoma and identification of an HLA-A∗25-restricted MHC class I ligand from solid tumor tissue, Cancer Biol. Ther., 4, 943, 10.4161/cbt.4.9.1907 Cole, 2009, Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor, J. Biol. Chem., 284, 27281, 10.1074/jbc.M109.022509 Barker, 2002, The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease, J. Neurosci. Res., 67, 705, 10.1002/jnr.10160 Hu, 2014, Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine, Cancer Immunol. Immunother., 63, 779, 10.1007/s00262-014-1551-x Bricard, 2005, Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma, J. Immunol., 174, 1709, 10.4049/jimmunol.174.3.1709 Mengus, 2013, MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas, Int. J. Cancer, 132, 2459, 10.1002/ijc.27914 Schultz-Thater, 2011, MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies, Int. J. Cancer, 129, 1137, 10.1002/ijc.25777 Sartorius, 2008, The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses, J. Immunol., 180, 3719, 10.4049/jimmunol.180.6.3719